Navigation Links
IDRI Awarded Contract from BARDA to Develop Next Generation Adjuvants for Pandemic Influenza
Date:12/3/2010

SEATTLE, Dec. 4, 2010 /PRNewswire-USNewswire/ -- The Infectious Disease Research Institute (IDRI) has been awarded an $1.8 million contract from the Biomedical Advance Research and Development Authority (BARDA). IDRI's work will focus on development of adjuvant formulations with options up to $8.5 million over three years when further development and manufacture of priority candidates are approved by the agency.

"BARDA is supporting an important expansion of IDRI's technology to solutions that address Neglected Diseases as well as those that affect us all in the United States," says Dr. Darrick Carter, Director of Formulations at IDRI and Principal Investigator on the BARDA influenza contract. Adjuvants and other immunostimulants can improve the body's immune response to diseases like influenza, in turn, reducing the amount of vaccine needed for protection (dose-sparing). The use of adjuvants will allow for expansion of vaccine supply to meet the necessary global demands during a pandemic.

BARDA is within the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response. The project is part of the innovations portfolio awarded out of BARDA's Strategic Science and Technology Division's Innovation BAA (Broad Agency Announcement).

About IDRI's Adjuvants

Adjuvants are compounds used to improve the body's immune response to vaccines. Adjuvant technology is proving invaluable in the development of vaccines for serious diseases for which vaccines are not currently available, including malaria and HIV.

Adjuvants are a key research component of IDRI's malaria, tuberculosis, leishmaniasis and leprosy vaccine development programs — supported by the Bill and Melinda Gates Foundation, the National Institutes of Health, and the American Leprosy Missions.

About IDRI – Translating science into global health solutions

IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty. By integrating capabilities — including preclinical vaccinology, manufacturing, and clinical trials — IDRI strives to create an efficient pathway bringing scientific innovation from the lab to the people who need it most.

For more information, go to www.idri.org  


'/>"/>
SOURCE Infectious Disease Research Institute (IDRI)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
2. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
3. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
4. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
5. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
6. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
7. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
8. DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia
9. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
10. New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity
11. TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):